Regulation of Complement C3 Expression by the Bile Acid Receptor FXR

Jiali Li, P Pircher, Ira G. Schulman, Stefan Westin

Journal of Biological Chemistry · 2004 · 93 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

The farnesoid X receptor (FXR; NR1H4) is an intracellular bile acid-sensing transcription factor that plays a critical role in the regulation of synthesis and transport of bile acids as well as lipid metabolism. Although the reciprocal relationship between bile acid and triglyceride levels is well known, the mechanism underlying this link is not clearly defined. In this study, we demonstrate that FXR regulates the expression of at least two secreted factors, complement component C3 and FGF15, the rat ortholog of FGF19, known to influence lipid metabolism. The analysis of the human complement C3 gene reveals the presence of functional FXR response elements in the proximal promoter of C3. Furthermore, rats given a single dose of an FXR agonist exhibit an increase in the plasma concentration of complement C3 protein. These studies demonstrate a mechanism by which FXR, a nuclear receptor with a limited tissue expression pattern, regulates secretion of factors that ultimately can affect lipid metabolism in an endocrine or paracrine manner. The farnesoid X receptor (FXR; NR1H4) is an intracellular bile acid-sensing transcription factor that plays a critical role in the regulation of synthesis and transport of bile acids as well as lipid metabolism. Although the reciprocal relationship between bile acid and triglyceride levels is well known, the mechanism underlying this link is not clearly defined. In this study, we demonstrate that FXR regulates the expression of at least two secreted factors, complement component C3 and FGF15, the rat ortholog of FGF19, known to influence lipid metabolism. The analysis of the human complement C3 gene reveals the presence of functional FXR response elements in the proximal promoter of C3. Furthermore, rats given a single dose of an FXR agonist exhibit an increase in the plasma concentration of complement C3 protein. These studies demonstrate a mechanism by which FXR, a nuclear receptor with a limited tissue expression pattern, regulates secretion of factors that ultimately can affect lipid metabolism in an endocrine or paracrine manner. Nuclear hormone receptors comprise a superfamily of transcription factors that is usually activated by small lipophilic ligands (1Committee Nuclear Receptor Nomenclature Cell. 1999; 97: 161-163Abstract Full Text Full Text PDF PubMed Scopus (940) Google Scholar). These receptors bind to specific cis-acting elements in their target genes influencing development, differentiation, and physiological homeostasis (2Mangelsdorf D.J. Thummel C. Beato M. Herrlich P. Schutz G. Umesono K. Blumberg B. Kastner P. Mark M. Chambon P. Evans R.M. Cell. 1995; 83: 835-839Abstract Full Text PDF PubMed Scopus (6064) Google Scholar). The nuclear receptor superfamily can be divided into three categories. The first category includes the classical steroid hormone receptors activated by high affinity ligands. The second group includes true orphan receptors for which no physiological ligand has been discovered. The third category corresponds to receptors such as peroxisome proliferator-activated receptors, liver X receptors, farnesoid X receptor (FXR), 1The abbreviations used are: FXR, farnesoid X receptor; BSEP, bile salt export pump; CDCA, 3α,7α-dihydroxy-5β-cholanic acid; C3, complement C3; ASP, acylation stimulating protein; WAT, white adipocyte tissue; RT, reverse transcription; SHP, small heterodimer partner; IBABP, ileal bile acid-binding protein; 6FAM, 6-carboxyfluorescein; TAMRA, carboxytetramethylrhodamine; FXRE, farnesoid X receptor element; LDLR, low density lipoprotein receptor.1The abbreviations used are: FXR, farnesoid X receptor; BSEP, bile salt export pump; CDCA, 3α,7α-dihydroxy-5β-cholanic acid; C3, complement C3; ASP, acylation stimulating protein; WAT, white adipocyte tissue; RT, reverse transcription; SHP, small heterodimer partner; IBABP, ileal bile acid-binding protein; 6FAM, 6-carboxyfluorescein; TAMRA, carboxytetramethylrhodamine; FXRE, farnesoid X receptor element; LDLR, low density lipoprotein receptor. steroid xenobiotic receptor/pregnane X receptor, and constitutive androstane receptor. These receptors are activated by dietary low-affinity ligands and have recently been defined as metabolic sensors (3Chawla A. Repa J.J. Evans R.M. Mangelsdorf D.J. Science. 2001; 294: 1866-1870Crossref PubMed Scopus (1685) Google Scholar). FXR (NR1H4) is a nuclear receptor that is bound and activated by specific bile acids at physiological concentrations (4Makishima M. Okamoto A.Y. Repa J.J. Tu H. Learned R.M. Luk A. Hull M.V. Lustig K.D. Mangelsdorf D.J. Shan B. Science. 1999; 284: 1362-1365Crossref PubMed Scopus (2145) Google Scholar, 5Parks D.J. Blanchard S.G. Bledsoe R.K. Chandra G. Consler T.G. Kliewer S.A. Stimmel J.B. Willson T.M. Zavacki A.M. Moore D.D. Lehmann J.M. Science. 1999; 284: 1365-1368Crossref PubMed Scopus (1829) Google Scholar, 6Wang H. Chen J. Hollister K. Sowers L.C. Forman B.M. Mol. Cell. 1999; 3: 543-553Abstract Full Text Full Text PDF PubMed Scopus (1283) Google Scholar). FXR controls bile acid concentrations in the liver by inhibiting the expression of CYP7A1 encoding cholesterol 7-α-hydroxylase, the rate-limiting enzyme in bile acid synthesis, and Na(+)/taurocholate cotransporting peptide, a transporter responsible for bile acid uptake. Additionally, FXR induces the expression of the bile salt export pump (BSEP). Together these changes in gene expression result in a net efflux of bile acids from the hepatocyte into bile (7Ananthanarayanan M. Balasubramanian N. Makishima M. Mangelsdorf D.J. Suchy F.J. J. Biol. Chem. 2001; 276: 28857-28865Abstract Full Text Full Text PDF PubMed Scopus (650) Google Scholar, 8Goodwin B. Jones S.A. Price R.R. Watson M.A. McKee D.D. Moore L.B. Galardi C. Wilson J.G. Lewis M.C. Roth M.E. Maloney P.R. Willson T.M. Kliewer S.A. Mol. Cell. 2000; 6: 517-526Abstract Full Text Full Text PDF PubMed Scopus (1500) Google Scholar, 9Lu T.T. Makishima M. Repa J.J. Schoonjans K. Kerr T.A. Auwerx J. Mangelsdorf D.J. Mol. Cell. 2000; 6: 507-515Abstract Full Text Full Text PDF PubMed Scopus (1216) Google Scholar). Furthermore, FXR controls the accumulation of toxic bile acids by inducing bile acid-amino acid conjugation and the conversion of hydrophobic bile acids into more hydrophilic less toxic glucuronide derivates (10Pircher P.C. Kitto J.L. Petrowski M.L. Tangirala R.K. Bischoff E.D. Schulman I.G. Westin S.K. J. Biol. Chem. 2003; 278: 27703-27711Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar, 11Barbier O. Torra I.P. Sirvent A. Claudel T. Blanquart C. Duran-Sandoval D. Kuipers F. Kosykh V. Fruchart J.C. Staels B. Gastroenterology. 2003; 124: 1926-1940Abstract Full Text Full Text PDF PubMed Scopus (167) Google Scholar). The recent identification of bile acids as physiological ligands for FXR may explain studies performed more than 20 years ago in which chenodeoxycholate (3α,7α-dihydroxy-5β-cholanic acid) (CDCA) given to patients with gallstones lowered plasma triglycerides (12Bateson M.C. Maclean D. Evans J.R. Bouchier I.A. Br. J. Clin. Pharmacol. 1978; 5: 249-254Crossref PubMed Scopus (71) Google Scholar, 13Iser J.H. Sali A. Drugs. 1981; 21: 90-119Crossref PubMed Scopus (60) Google Scholar). In addition, bile acid-binding resins are known to induce the production of very low density lipoprotein triglycerides underscoring the importance of bile acids in maintaining triglyceride homeostasis (14Angelin B. Einarsson K. Hellstrom K. Leijd B. J. Lipid Res. 1978; 19: 1017-1024Abstract Full Text PDF PubMed Google Scholar). The demonstration that plasma triglycerides are elevated in FXR knock-out mice and that a synthetic FXR agonist causes a 50% reduction in triglycerides in rats clearly establish a role for FXR in lipid metabolism (15Sinal C.J. Tohkin M. Miyata M. Ward J.M. Lambert G. Gonzalez F.J. Cell. 2000; 102: 731-744Abstract Full Text Full Text PDF PubMed Scopus (1410) Google Scholar, 16Lambert G. Amar M.J. Guo G. Brewer Jr., H.B. Gonzalez F.J. Sinal C.J. J. Biol. Chem. 2003; 278: 2563-2570Abstract Full Text Full Text PDF PubMed Scopus (312) Google Scholar, 17Maloney P.R. Parks D.J. Haffner C.D. Fivush A.M. Chandra G. Plunket K.D. Creech K.L. Moore L.B. Wilson J.G. Lewis M.C. Jones S.A. Willson T.M. J. Med. Chem. 2000; 43: 2971-2974Crossref PubMed Scopus (457) Google Scholar). Furthermore, the induction of apolipoprotein CII and the simultaneous repression of apolipoprotein CIII in the liver by FXR ligands represent an important pathway for the clearance of plasma triglycerides (18Kast H.R. Nguyen C.M. Sinal C.J. Jones S.A. Laffitte B.A. Reue K. Gonzalez F.J. Willson T.M. Edwards P.A. Mol. Endocrinol. 2001; 15: 1720-1728Crossref PubMed Scopus (224) Google Scholar, 19Claudel T. Inoue Y. Barbier O. Duran-Sandoval D. Kosykh V. Fruchart J. Fruchart J.C. Gonzalez F.J. Staels B. Gastroenterology. 2003; 125: 544-555Abstract Full Text Full Text PDF PubMed Scopus (208) Google Scholar). Nevertheless, the expression of apoCII and apoCIII is not significantly altered in FXR knock-out mice, suggesting that FXR may utilize multiple mechanisms to regulate plasma triglyceride levels. For instance, recent evidence suggests that FXR can regulate fattyacid synthesis through an indirect mechanism involving SHP, liver X receptor, and sterol regulatory element-binding protein-1C (20Watanabe M. Houten S.M. Wang L. Moschetta A. Mangelsdorf D.J. Heyman R.A. Moore D.D. Auwerx J. J. Clin. Investig. 2004; 113: 1408-1418Crossref PubMed Scopus (972) Google Scholar). Similarly, the identification of FGF19, a known regulator of metabolic rate, as an FXR target gene suggests that FXR may indirectly regulate lipid metabolism by controlling the expression of secreted factors (21Holt J.A. Luo G. Billin A.N. Bisi J. McNeill Y.Y. Kozarsky K.F. Donahee M. Wang da Y. Mansfield T.A. Kliewer S.A. Goodwin B. Jones S.A. Genes Dev. 2003; 17: 1581-1591Crossref PubMed Scopus (532) Google Scholar). Interestingly, lipids in the form of polyunsaturated fatty acids may in fact be endogenous FXR ligands and thus may act to limit their own synthesis (22Zhao A. Yu J. Lew J.L. Huang L. Wright S.D. Cui J. DNA Cell Biol. 2004; 23: 519-526Crossref PubMed Scopus (103) Google Scholar). Here we report that complement C3 (C3) and fgf15, the mouse ortholog of FGF19 (23Wright T.J. Ladher R. McWhirter J. Murre C. Schoenwolf G.C. Mansour S.L. Dev. Biol. 2004; 269: 264-275Crossref PubMed Scopus (110) Google Scholar), are direct FXR target genes. C3 in addition to its role in innate immunity is a precursor for acylation stimulating protein (ASP) (24Cianflone K. Xia Z. Chen L.Y. Biochim. Biophys. Acta. 2003; 1609: 127-143Crossref PubMed Scopus (314) Google Scholar). Produced by adipocytes in response to a fat-containing meal, ASP acts in a paracrine fashion to increase fatty acid uptake and triglyceride synthesis. The identification of C3 as an FXR target gene suggests a previously unknown link between FXR and complement activation and further supports a described previously link among complement activation, lipid metabolism, and atherosclerosis. Cell Cultures—Fao (a designated rat hepatoma cell derived from rat H4IIE cells), Caco-2, and CV-1 cells were obtained from ATCC and maintained according to its depository. Cells were treated with vehicle (Me2SO) or the following FXR ligands: 100 μm 3α,7α-dihydroxy-5β-cholanic acid (CDCA) and 1 μm 3-(2,6-dichlorophenyl)-4-(3′-carboxy-2-chloro-stilben-4-yl)oxymethyl-5-isopropyl-isoxazole (GW4064) (17Maloney P.R. Parks D.J. Haffner C.D. Fivush A.M. Chandra G. Plunket K.D. Creech K.L. Moore L.B. Wilson J.G. Lewis M.C. Jones S.A. Willson T.M. J. Med. Chem. 2000; 43: 2971-2974Crossref PubMed Scopus (457) Google Scholar). After 20 h, total RNA was isolated from the FAO and Caco-2 cells. RNA Isolation and mRNA Quantitation—Total RNA was isolated from rat and mouse liver, intestinal mucosa, mouse white adipocyte tissue (WAT), Fao, and Caco-2 cells using TRIzol reagent (Invitrogen) and further purified by using an RNeasy kit (Qiagen, Valencia, CA). For Northern analysis, total RNA (20 μg) was resolved on a 1% agarose/formaldehyde gel, transferred to nylon membrane, and cross-linked to the membrane with UV-light. cDNA probes were radiolabeled with [α-32P]dCTP using the Rediprime II labeling kit (Amersham Biosciences). Membranes were hybridized using the Rapid hybridization buffer (Amersham Biosciences), washed according to the manufacturer, and quantified using a Molecular Imager (Bio-Rad). TaqMan Primers and Probes—Oligonucleotide primers and the probes for mouse complement C3, fgf15, SHP, IBABP, FXR, rat and and human FGF19 were using the and by DNA The were as C3 and reverse and reverse FGF19 and reverse and reverse mouse and reverse rat and reverse mouse and reverse and mouse FXR and reverse cDNA and cDNA for complement C3 was from rat liver mRNA using primers and to of the rat The was radiolabeled and used as a for Northern cDNA for was from mouse intestinal mRNA using primers and to of the The was radiolabeled and used as a for Northern The promoter of the human promoter and was a from Moore of promoter in with primers as described previously (7Ananthanarayanan M. Balasubramanian N. Makishima M. Mangelsdorf D.J. Suchy F.J. J. Biol. Chem. 2001; 276: 28857-28865Abstract Full Text Full Text PDF PubMed Scopus (650) Google Scholar). complement C3 and gene were obtained from of promoter and of C3 gene was from human DNA using primers and and into of of the in the C3 gene was using the kit from with the and a are in in a according to the of the primers were from DNA The of of the were by DNA and cells were using the reagent of of of and of and of were used in a of After a at the was to cells in and for at The cells were treated with and vehicle (Me2SO) or of the following ligands: 100 μm or 1 μm After 20 h, cells were and for and The were by the by the of C3 and are in were radiolabeled with [α-32P]dCTP using the of DNA and were from and expression using the 20 1 of of receptor and of were at a The used as for the C3 for mouse and for rat is and the is in The for human and were as described previously (1Committee Nuclear Receptor Nomenclature Cell. 1999; 97: 161-163Abstract Full Text Full Text PDF PubMed Scopus (940) Google Scholar, D.J. Thummel C. Beato M. Herrlich P. Schutz G. Umesono K. Blumberg B. Kastner P. Mark M. Chambon P. Evans R.M. Cell. 1995; 83: 835-839Abstract Full Text PDF PubMed Scopus (6064) Google Scholar). from rats μg) was by in and on an gel, and were to a nylon The was with a the protein and using a with and were according to of for the and of rats and mice were and were The was in vehicle for a of 1 for rats and for were given a single dose with a to a concentration of 100 The were following the and liver, small and were The intestinal from the small were in and at RNA and intestinal from FXR mice (3Chawla A. Repa J.J. Evans R.M. Mangelsdorf D.J. Science. 2001; 294: 1866-1870Crossref PubMed Scopus (1685) Google more than into mice, and mice was a from of C3 and FGF19 by FXR analysis of from rat that the gene encoding C3 is by (CDCA) and synthetic FXR (GW4064) (10Pircher P.C. Kitto J.L. Petrowski M.L. Tangirala R.K. Bischoff E.D. Schulman I.G. Westin S.K. J. Biol. Chem. 2003; 278: 27703-27711Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar). The induction of C3 was by Northern analysis in Fao, a rat hepatoma cell and in Caco-2, a human FXR The regulation of C3 in intestinal cells was the liver is the of we FGF19, secreted factor previously to be a FXR target gene in (21Holt J.A. Luo G. Billin A.N. Bisi J. McNeill Y.Y. Kozarsky K.F. Donahee M. Wang da Y. Mansfield T.A. Kliewer S.A. Goodwin B. Jones S.A. Genes Dev. 2003; 17: 1581-1591Crossref PubMed Scopus (532) Google Scholar), is in Caco-2 cells. in FGF19 is significantly by FXR ligands in these suggesting that FXR in the may influence lipid metabolism by the synthesis and secretion of these of in C3 and induction of C3 mRNA by and suggests that this gene is a direct target of FXR for elements to an of the by a of the in the human C3 gene as well as the is in rat and mouse C3 genes. has been to be the mouse ortholog of human FGF19 the low acid rat and mouse in a that was for human FGF19 demonstrate that bind the in the proximal human C3 and in the were DNA to the from the human C3 and genes were and for to bind a is on the C3 and that is not with receptor Additionally, is by an of their affinity studies that bind to the with affinity with the C3 as by a of the for to the C3 the are on the for C3 and and human gene were and the of FXR to expression was by into CV-1 cells. The from the human C3 gene FXR by the increase in cells are treated with and ligands in the presence of FXR and The by FXR C3 to the known FXR target genes and a affinity on the the induction of the C3 promoter by FXR ligands is with the activation of and of of the C3 of the FXR not the of the C3 promoter of C3 and in FXR regulates C3 expression in C3 mRNA levels were in and In the of FXR in levels of C3 mRNA Although is a for levels of C3 mRNA in the liver of mice, expression levels were not significantly from mice The high levels of C3 expression in the liver, the in the may to an of In mice treated with a single dose of an induction of C3 mRNA was in intestinal mucosa, a small induction was in the liver of these and The expression of C3 mRNA in WAT, the target tissue for ASP of was high with the a increase in C3 mRNA expression was in response to The low expression of FXR mRNA in with the liver and may for the increase in this tissue a of and activation of FXR C3 as a target gene in Although expression levels not significantly between and mice not mRNA levels were by in the mouse was to be the ortholog of FGF19, was not in the liver not The two target genes and were in liver and of in these and Northern analysis a induction of C3 and mRNA expression in the of rats that was given a single dose of The of C3 in plasma is to be the liver, secretion from has been 6: Google Scholar). was in mice, rat liver C3 levels were by an FXR of high mRNA expression levels in this tissue not of the of C3, plasma levels were in rats treated with the FXR agonist in mice, and mRNA levels in the liver and and these that regulation of C3 in the may indirectly influence lipid metabolism at In this study, we have complement C3 as a FXR target that C3 is in cell of and intestinal and that regulation of C3 by FXR in the small in of C3 was in the that FXR mRNA levels are less in this tissue to liver and Y. H.R. Edwards P.A. J. Biol. Chem. 2003; 278: Full Text Full Text PDF PubMed Scopus Google may to the with levels of and adipocyte C3 from tissue specific factors endogenous fatty FXR ligands (22Zhao A. Yu J. Lew J.L. Huang L. Wright S.D. Cui J. DNA Cell Biol. 2004; 23: 519-526Crossref PubMed Scopus (103) Google Scholar), may to an of synthetic ligands in these that the human and C3 genes of a an that bind to this and that the FXR of a C3 the genes encoding mouse and rat elements at an as the human FGF19 of FXR expression of C3 in the the importance of this nuclear receptor for regulation of C3. C3 and mRNA levels were in response to the FXR agonist in intestinal of mice and rats and C3 protein levels were in plasma of The to C3 used in these studies mouse C3; studies be to FXR increase plasma C3 levels in mice and is secreted into establish that FXR regulates the genes encoding for C3 and and to an important of the as a of Furthermore, the induction of human FGF19 in the Caco-2 cell suggests the as a of expression for this The from these studies is activation of target genes and ultimately secretion of factors from the a role in the of FXR ligands. FGF19 mice metabolic and L. L. B. Huang M. L. D. T.A. PubMed Scopus Google Scholar). a specific promoter was used to the FGF19 the target tissue for FGF19 is to be the suggests in the mice, FGF19 is in and secreted to its target The mouse of FGF19, fgf15, was by FXR in the than in the Although further studies are to establish as FGF19, studies in addition to C3, FXR regulates production of have in C3 is to by the of factors and and is by to which is to ASP acts in a paracrine fashion to increase fatty acid uptake and triglyceride synthesis in the adipocyte (24Cianflone K. Xia Z. Chen L.Y. Biochim. Biophys. Acta. 2003; 1609: 127-143Crossref PubMed Scopus (314) Google Scholar). Although C3 mRNA and protein levels are by FXR, we no evidence of an increase in plasma ASP of the FXR ligand in mice or The for this may be that ASP is by of C3 in the to an increase in plasma Furthermore, in the concentration of ASP in plasma is less than C3 (24Cianflone K. Xia Z. Chen L.Y. Biochim. Biophys. Acta. 2003; 1609: 127-143Crossref PubMed Scopus (314) Google Scholar). a small of C3 is to ASP in and may be to the the of ASP production is to be in the of ASP may be derived from C3 synthesis in Although has been that the liver is the of synthesis for C3 A.M. Moore Science. PubMed Scopus Google Scholar), induction of C3 mRNA in the small Although an increase in plasma C3 protein and mRNA not the functional of ASP, is to that an of C3 expression to fatty acid uptake in the the reduction of plasma triglyceride levels by FXR ligands may in be the of fatty acid uptake and triglyceride in C3, thus in ASP, have triglyceride clearance that can be by of ASP K. J. Lipid Res. 1999; Full Text Full Text PDF PubMed Google Scholar). Although these mice C3 and ASP, is no evidence to that C3 plays a direct role in lipid metabolism or Nevertheless, concentrations of C3 have been with lipid and levels N. Watson R.R. PubMed Scopus Google Scholar, S.L. M. Res. 6: PubMed Scopus Google Scholar, C. P.A. 2000; 23: PubMed Scopus (110) Google Scholar). with have elevated C3 not ASP K. P. R.M. N. J. Biol. 2001; 21: PubMed Scopus Google Scholar). These patients in addition to metabolic with an of fatty acids in Although C3 levels in may a ASP pathway in these response to C3 and fatty acid uptake may explain the fattyacid and very low density lipoprotein in The influence of complement activation on the of has been is well known that is with an response to the accumulation of and is evidence that complement activation is in F. H. Mol. 1999; PubMed Scopus Google Scholar). have been in the of and of complement factors are in A. J. Google Scholar, J. J.G. Scholar, R. F. A. Full Text PDF PubMed Scopus Google Scholar, M. Roth Full Text PDF PubMed Scopus Google Scholar). C3 mice were with mice and with high a in the with mice was C. J.L. M. PubMed Scopus Google Scholar). mice with mice in and have a that is with mice L. J. V. M. Biol. 2004; PubMed Scopus Google Scholar). The mice in an a more lipoprotein than controls with elevated triglyceride levels and very low density lipoprotein triglycerides and These that complement activation through the regulation of lipid metabolism and suggests that FXR ligands may be for the of atherosclerosis. In FXR regulates complement component C3, a factor in the pathway of complement activation and fgf15, the mouse ortholog of human FGF19 through a direct mechanism at the The activation of C3, a precursor of ASP, and in the may have on lipid metabolism and may in explain the of FXR ligands. and for the synthesis of Petrowski and for and and for with

References

32